Loading...
Surveillance of drug susceptibility in Clostridium difficile is important because of limited treatment options and lack of routine susceptibility testing in the clinical setting. Investigators in Leeds, England, recently examined metronidazole susceptibility in isolates from the most common ribotypes in 2005–2006 and compared the MICs with those of historical isolates from 1995–2001.
Median spiral gradient endpoint (SGE) analysis metronidazole MICs for C. difficile isolates from 2005–2006 were significantly higher for ribotype 001 than for ribotype 106 or 027 (P<0.001 for each). Reduced susceptibility, not observed in ribotype 106 or 027 isolates, was seen in 24.4% of ribotype 001 isolates.
The 22 C. difficile isolates with reduced metronidaz…